Clinical Trial

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Name: A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients — clinical trial record (NCT06335355)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations

Trial Details

NCT Number	NCT06335355
Lead Sponsor	Shanghai Shengdi Pharmaceutical Co., Ltd
Conditions	Non-squamous Non-small Cell Lung Cancer
Enrollment	401 participants
Start Date	2024-03
Primary Completion	2028-10 (estimated)
Study Completion	2030-10 (estimated)
Updated on ClinicalTrials.gov	2024-03-28